Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions
Condition: Healthy
Intervention: Losartan; Cozaar®
Intervention description: 100 mg Tablets; 100 mg Tablets
Intervention MeSH terms: Losartan
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 80.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      The objective of this study is to compare the rate and extent of absorption of losartan 100
      mg tablets (test) versus Cozaar® (reference), administered as 1 * 100 mg tablet under fed
      conditions.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Non-child-bearing potential female or male.

          -  Non-smoker

          -  18 years or age and older.

          -  Capable of consent.

          -  Non-child-bearing potential female subject:

               -  Post-menopausal state: absence of menses for 12 months prior to drug
                  administration.

               -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at
                  least 6 months prior to drug administration.

        Exclusion Criteria:

          -  Clinically significant illness within 4 weeks prior to the administration of the study
             medication.

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive urine drug screen at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities at screening.

          -  Subjects with BMI greater than or equal to 30.0.

          -  History of significant alcohol abuse within 6 months prior to the screening visit or
             any indication of the regular use of more than 14 units of alcohol per week (1 unit
             equals 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).

          -  History of drug abuse of use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months prior to the screening visit or hard drugs (such as cocaine,
             phencyclidine [PCP], or crack) within 1 year prior to the screening visit.

          -  History of allergic reactions to losartan or other related drugs.

          -  History of allergic reactions to heparin.

          -  Use of any drugs known to induce of inhibit drug metabolism within 30 days prior to
             administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion of the drug.

          -  Any clinically significant history or presence of neurological, endocrinal,
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic
             disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products within 7 days prior to administration of study
             medication, except for topical products without systemic absorption.

          -  Positive alcohol breath test at screening.

          -  Subjects who have used tobacco in any form within the 90 days preceding study drug
             administration.

          -  Any food allergy, intolerance, restriction, or special diet that could, in the opinion
             of the Medical Sub-Investigator, contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood prior to administration of study medication as follows:

               -  Less than 300 mL of whole blood within 30 days,

               -  300 mL to 500 mL of whole blood within 45 days, or

               -  More than 500 mL of whole blood within 56 days prior to drug administration.

          -  Consumption of food or beverages containing grapefruit within 7 days prior to
             administration of the study medication.

          -  Clinically significant history or known hypotension or volume depletion.

          -  Intolerance to venipuncture.

          -  Clinically significant history or renal, hepatic, or cardiovascular disease,
             tuberculosis, epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible
             for this study.

          -  Subjects who are unable to understand or unwilling to sign the Informed Consent Form.

          -  Additional exclusion criteria for females only:

               -  Breast-feeding subjects.

               -  Positive urine pregnancy test at screening (performed for all females).